Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Cytomegalovirus-specific CD8+ T-cell responses are associated with arterial blood pressure in people living with HIV

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Making the best of the worst: Care quality during emergency cesarean sections

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Seasonality of ventricular fibrillation at first myocardial infarction and association with viral exposure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Antibiotic treatment adequacy and death among patients with Pseudomonas aeruginosa airway infection

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
Pathogenic germline mutations in BRCA1 or BRCA2 are detected in less than one third of families with a strong history of breast cancer. It is therefore expected that mutations still remain undetected by currently used screening methods. In addition, a growing number of BRCA1/2 sequence variants of unclear pathogen significance are found in the families, constituting an increasing clinical challenge. New methods are therefore needed to improve the detection rate and aid the interpretation of the clinically uncertain variants. In this study we analyzed a series of 33 BRCA1, 22 BRCA2, and 128 sporadic tumors by RNA profiling to investigate the classification potential of RNA profiles to predict BRCA1/2 mutation status. We found that breast tumors from BRCA1 and BRCA2 mutation carriers display characteristic RNA expression patterns, allowing them to be distinguished from sporadic tumors. The majority of BRCA1 tumors were basal-like while BRCA2 tumors were mainly luminal B. Using RNA profiles, we were able to distinguish BRCA1 tumors from sporadic tumors among basal-like tumors with 83% accuracy and BRCA2 from sporadic tumors among luminal B tumors with 89% accuracy. Furthermore, subtype-specific BRCA1/2 gene signatures were successfully validated in two independent data sets with high accuracies. Although additional validation studies are required, indication of BRCA1/2 involvement ("BRCAness") by RNA profiling could potentially be valuable as a tool for distinguishing pathogenic mutations from benign variants, for identification of undetected mutation carriers, and for selecting patients sensitive to new therapeutics such as PARP inhibitors.
OriginalsprogEngelsk
TidsskriftP L o S One
Vol/bind8
Udgave nummer5
Sider (fra-til)e64268
ISSN1932-6203
DOI
StatusUdgivet - 2013

ID: 42317464